MCID: CLR109
MIFTS: 54

Colorectal Adenocarcinoma

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Colorectal Adenocarcinoma

MalaCards integrated aliases for Colorectal Adenocarcinoma:

Name: Colorectal Adenocarcinoma 12 15
Adenocarcinoma of Large Intestine 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0050861
UMLS 73 C1319315

Summaries for Colorectal Adenocarcinoma

Disease Ontology : 12 A colorectal carcinoma that derives from epithelial cells of glandular origin.

MalaCards based summary : Colorectal Adenocarcinoma, also known as adenocarcinoma of large intestine, is related to adenocarcinoma and colorectal adenoma. An important gene associated with Colorectal Adenocarcinoma is FABP6 (Fatty Acid Binding Protein 6), and among its related pathways/superpathways are Developmental Biology and fMLP Pathway. The drugs Iron and Ferric Compounds have been mentioned in the context of this disorder. Affiliated tissues include liver, colon and lymph node, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Colorectal Adenocarcinoma

Diseases related to Colorectal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 302)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 31.4 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
2 colorectal adenoma 31.3 CTNNB1 HRAS KRAS MLH1 MSH2 TP53
3 gastrointestinal stromal tumor 30.5 BRAF EGFR KRAS TP53
4 renal cell carcinoma, nonpapillary 30.1 CDH1 EGFR KRT20 KRT7
5 chordoma 30.0 CDH1 EGFR KRT7
6 villous adenoma 29.9 BRAF CDX2 KRAS KRT20
7 adenoma 29.9 BRAF CTNNB1 KRAS MLH1 MSH2 TP53
8 mucinous bronchioloalveolar adenocarcinoma 29.8 CDX2 KRT20 KRT7
9 squamous cell carcinoma 29.6 BRAF CDH1 CTNNB1 EGFR HRAS TP53
10 bladder adenocarcinoma 29.5 CDX2 CTNNB1 HRAS KRT20 KRT7
11 familial adenomatous polyposis 29.5 CDH1 CTNNB1 KRAS MLH1 MSH2 TP53
12 ulcerative colitis 29.4 CTNNB1 MLH1 MSH2 MUC2
13 lynch syndrome 29.3 BRAF CTNNB1 EGFR KRAS MLH1 MSH2
14 mucinous adenocarcinoma 29.3 CDX2 EGFR KRAS KRT20 KRT7 MLH1
15 hepatocellular carcinoma 29.1 CDH1 CEACAM5 CTNNB1 EGFR HRAS KRAS
16 esophageal cancer 29.0 CDH1 CDX2 CEACAM5 CTNNB1 EGFR HRAS
17 lung cancer 28.9 BRAF CDH1 CEACAM5 EGFR HRAS KRAS
18 lung cancer susceptibility 3 28.7 BRAF CDH1 CDX2 CEACAM5 CTNNB1 EGFR
19 cholangiocarcinoma 28.7 BRAF CDH1 CDX2 CEACAM5 CTNNB1 EGFR
20 colorectal cancer 28.5 AURKA BRAF CDH1 CDX2 CEACAM5 CTNNB1
21 gastric adenocarcinoma 28.3 BRAF CDH1 CDX2 CEACAM5 CTNNB1 EGFR
22 intestinal disease 28.3 CDH1 CDX2 CEACAM5 CTNNB1 EGFR HRAS
23 nevus of ota 10.4 BRAF TP53
24 rare adenocarcinoma of the breast 10.4 KRAS TP53
25 vulvar intraepithelial neoplasia 10.4 KRT7 TP53
26 seminal vesicle adenocarcinoma 10.4 KRT20 KRT7
27 transverse colon cancer 10.4 KRT20 KRT7
28 colloid adenoma 10.4 KRT20 TP53
29 papillary transitional carcinoma 10.4 KRT20 KRT7
30 cystic basal cell carcinoma 10.4 KRT20 KRT7
31 malignant syringoma 10.3 KRT20 KRT7
32 krukenberg carcinoma 10.3 KRT20 KRT7
33 small cell carcinoma of the bladder 10.3 KRT20 KRT7
34 ovary neuroendocrine neoplasm 10.3 CDX2 KRT7
35 vaginal benign neoplasm 10.3 CDX2 KRT20
36 vaginal adenoma 10.3 CDX2 KRT20
37 vaginal tubulovillous adenoma 10.3 CDX2 KRT20
38 cerebral convexity meningioma 10.3 CDH1 TP53
39 renal pelvis adenocarcinoma 10.3 CDH1 KRT7
40 brain ependymoma 10.3 EGFR TP53
41 benign breast adenomyoepithelioma 10.3 EGFR KRT7
42 oncocytic breast carcinoma 10.3 EGFR KRT7
43 intracranial chondrosarcoma 10.3 CEACAM5 TP53
44 cutaneous mucoepidermoid carcinoma 10.3 CEACAM5 KRT7
45 anal gland adenocarcinoma 10.3 CEACAM5 KRT7
46 anal paget's disease 10.3 CDX2 CEACAM5
47 ovarian clear cell carcinoma 10.3 KRAS KRT7 TP53
48 esophageal adenosquamous carcinoma 10.3 CDH1 CEACAM5
49 sweat gland cancer 10.3 KRT20 KRT7 TP53
50 adult hepatocellular carcinoma 10.3 CTNNB1 TP53

Graphical network of the top 20 diseases related to Colorectal Adenocarcinoma:



Diseases related to Colorectal Adenocarcinoma

Symptoms & Phenotypes for Colorectal Adenocarcinoma

GenomeRNAi Phenotypes related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.92 AURKA EGFR HRAS KRAS PIM2 BRAF
2 Decreased viability GR00106-A-0 10.92 KRAS
3 Decreased viability GR00173-A 10.92 CDK8
4 Decreased viability GR00221-A-1 10.92 AURKA CDH1 CDK8 EGFR HRAS KRAS
5 Decreased viability GR00221-A-2 10.92 AURKA CDK8 HRAS KRAS
6 Decreased viability GR00221-A-3 10.92 HRAS
7 Decreased viability GR00221-A-4 10.92 AURKA CDK8 EGFR BRAF
8 Decreased viability GR00231-A 10.92 AURKA
9 Decreased viability GR00301-A 10.92 CDH1 CDK8 KRAS PIM2 BRAF MSH2
10 Decreased viability GR00381-A-1 10.92 KRAS BRAF
11 Decreased viability GR00402-S-2 10.92 AURKA CDH1 CDK8 EGFR HRAS KRAS
12 Decreased cell migration GR00055-A-1 9.97 AURKA BRAF CDK8 CTNNB1 EGFR HRAS
13 Decreased viability in esophageal squamous lineage GR00235-A 9.9 AURKA BRAF CDH1 CDK8 CTNNB1 FABP6
14 Decreased cella89culturea89derived Hepatitis C virus (HCVcc; Luca89Jc1) infection GR00234-A-2 9.5 BRAF CDK8 EGFR
15 Increased cell migration GR00055-A-3 9.43 AURKA BRAF CTNNB1 EGFR HRAS KRAS
16 Increased cell viability after pRB stimulation GR00230-A-1 8.92 AURKA CDK8 EGFR PIM2

MGI Mouse Phenotypes related to Colorectal Adenocarcinoma:

46 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.27 AURKA BRAF CDH1 CDX2 CTNNB1 EGFR
2 digestive/alimentary MP:0005381 10.22 BRAF CDH1 CDX2 CTNNB1 EGFR HRAS
3 homeostasis/metabolism MP:0005376 10.22 BRAF CDH1 CDX2 CTNNB1 EGFR FABP6
4 mortality/aging MP:0010768 10.17 AURKA BRAF CDH1 CDK8 CDX2 CTNNB1
5 endocrine/exocrine gland MP:0005379 10.13 BRAF CDH1 CDX2 CTNNB1 EGFR HRAS
6 embryo MP:0005380 10.11 AURKA BRAF CDH1 CDK8 CDX2 CTNNB1
7 neoplasm MP:0002006 10.03 AURKA BRAF CDH1 CDX2 CTNNB1 EGFR
8 integument MP:0010771 10.02 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
9 no phenotypic analysis MP:0003012 9.7 AURKA CDH1 CTNNB1 EGFR HRAS KRAS
10 pigmentation MP:0001186 9.35 BRAF CTNNB1 EGFR KRAS TP53
11 renal/urinary system MP:0005367 9.17 BRAF CTNNB1 EGFR HRAS KRAS KRT7

Drugs & Therapeutics for Colorectal Adenocarcinoma

Drugs for Colorectal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 141)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iron Approved Phase 4 7439-89-6 23925
2 Ferric Compounds Phase 4
3 Hematinics Phase 4,Phase 3,Phase 2,Phase 1
4 Hepcidins Phase 4
5 Iron Supplement Phase 4
6
Oxaliplatin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 61825-94-3 43805 6857599 5310940 9887054
7
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 216974-75-3
8
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
9
Levoleucovorin Approved, Investigational Phase 3,Phase 2,Phase 1 68538-85-2
10
Fluorouracil Approved Phase 3,Phase 2,Phase 1,Not Applicable 51-21-8 3385
11
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 6006 143
12
Irinotecan Approved, Investigational Phase 2, Phase 3,Phase 1 100286-90-6, 97682-44-5 60838
13
Atezolizumab Approved, Investigational Phase 3,Phase 2 1380723-44-3
14
Nicotine Approved Phase 3 54-11-5 942 89594
15
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 59-30-3 6037
16
Glutamic Acid Approved, Nutraceutical Phase 3 56-86-0 33032
17 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
18 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
19 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
20 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1,Not Applicable
21 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
22 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
23 Protective Agents Phase 3,Phase 2,Phase 1,Not Applicable
24 Calcium, Dietary Phase 3,Phase 2
25 Antidotes Phase 3,Phase 2,Phase 1,Not Applicable
26 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
27 Antibodies Phase 3,Phase 2,Phase 1
28 Immunoglobulins Phase 3,Phase 2,Phase 1
29 Liver Extracts Phase 3,Phase 2,Phase 1,Not Applicable
30 Pharmaceutical Solutions Phase 3,Phase 2
31 Micronutrients Phase 3,Phase 2,Phase 1,Not Applicable
32 Vitamin B9 Phase 3,Phase 2,Phase 1,Not Applicable
33 Vitamins Phase 3,Phase 2,Phase 1,Not Applicable
34 Trace Elements Phase 3,Phase 2,Phase 1,Not Applicable
35 Folate Phase 3,Phase 2,Phase 1,Not Applicable
36 Vitamin B Complex Phase 3,Phase 2,Phase 1,Not Applicable
37 Bone Density Conservation Agents Phase 3,Phase 2
38 Immunoglobulin G Phase 3,Phase 2
39 Endothelial Growth Factors Phase 3,Phase 2
40 Mitogens Phase 3,Phase 2,Phase 1
41 Tetrahydrofolates Phase 3
42 Formyltetrahydrofolates Phase 3
43 Mitomycins Phase 2, Phase 3
44
s 1 (combination) Phase 3
45
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
46
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
47
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616
48
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
49
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
50
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631

Interventional clinical trials:

(show top 50) (show all 133)
# Name Status NCT ID Phase Drugs
1 Intravenous Iron: Measuring Response in Anemic Surgical Patients Completed NCT02057471 Phase 4 Intravenous ferric carboxymaltose
2 IVICA: Intravenous Iron in Colorectal Cancer Associated Anaemia Completed NCT01701310 Phase 4 Ferric carboxymaltose;Ferrous Sulphate
3 A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370) Completed NCT02788279 Phase 3 Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody;Cobimetinib;Regorafenib
4 Impact of Positron Emission Tomography Imaging Prior to Liver Resection for Colorectal Adenocarcinoma Metastases Completed NCT00265356 Phase 3
5 A Study of Avastin (Bevacizumab) and Xeloda (Capecitabine) as Maintenance Treatment in Patients With Metastatic Colorectal Cancer Completed NCT00623805 Phase 3 Bevacizumab;Capecitabine;Oxaliplatin
6 Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM Recruiting NCT03125161 Phase 3 HAI;chemotherapy ± target therapy
7 Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer Recruiting NCT02997228 Phase 3 Atezolizumab;Fluorouracil;Leucovorin Calcium;Oxaliplatin
8 5-FU Based Maintenance Therapy in RAS Wild Type Metastatic Colorectal Cancer After Induction With FOLFOX Plus Panitumumab Recruiting NCT03300609 Phase 3 Oxaliplatin;Leucovorin Calcium;Fluorouracil;Capecitabine
9 Perioperative Systemic Therapy for Isolated Resectable Colorectal Peritoneal Metastases Recruiting NCT02758951 Phase 2, Phase 3
10 Safety and Efficacy Study of Famitinib in Patients With Advanced Colorectal Adenocarcinoma(FACT) Active, not recruiting NCT02390947 Phase 3 Famitinib;Placebo
11 Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal Adenocarcinoma Not yet recruiting NCT03708536 Phase 3 S-1;Bevacizumab;Capecitabine
12 TACE(Transcatheter Arterial Chemoembolization ) Associated With Systemic Chemotherapy Versus Systemic Chemotherapy Alone in Patients With Unresectable CRLM(Colorectal Liver Metastases) Not yet recruiting NCT03783559 Phase 3 TACE;chemotherapy±target therapy
13 Efficacy and Safety Study of a Modified XELOX Regimen in First-Line Treatment of Metastatic Colorectal Adenocarcinoma Unknown status NCT01552967 Phase 2 Capecitabine
14 Phase II Study Evaluating the Efficacy and the Safety of Regorafenib in Patients Aged More Than 70 Years With a Metastatic Colorectal Adenocarcinoma . Unknown status NCT02788006 Phase 2 Regorafenib 160 mg
15 Efficacy/Safety Study of Bevacizumab,Capecitabine,Oxaliplatin to Metastatic Colorectal Adenocarcinoma Elderly Patients. Unknown status NCT01067053 Phase 2 bevacizumab, capecitabine, oxaliplatin
16 Neoadjuvant Radiation Therapy and Capecitabine in Treating Patients With Stage III or Stage IV Colorectal Adenocarcinoma Unknown status NCT00075556 Phase 2 capecitabine
17 Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00544011 Phase 2 capecitabine;fluorouracil;irinotecan hydrochloride
18 Capecitabine and Oxaliplatin in Treating Older Patients With Metastatic Colorectal Cancer Unknown status NCT00104689 Phase 2 capecitabine;oxaliplatin
19 Vaccine Therapy and Chemotherapy With or Without Tetanus Toxoid Compared With Chemotherapy Alone in Treating Patients With Metastatic Colorectal Cancer Unknown status NCT00027833 Phase 2 FOLFIRI regimen;fluorouracil;irinotecan hydrochloride;leucovorin calcium
20 Safety and Efficacy of S-8184 in Second Line Treatment of Stage III or IV Colorectal Adenocarcinoma Completed NCT00034190 Phase 2 S-8184 Paclitaxel Injectable Emulsion
21 Evaluation of Bevacizumab in Combination With First-Line Chemotherapy in Patients Aged 75 Years of Older With Metastatic Colorectal Adenocarcinoma (Prodige20) Completed NCT01900717 Phase 2 LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified;LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks
22 Study of 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma Completed NCT00168155 Phase 2 perioperative chemotherapy
23 Study to Assess Safety and Tolerability of G17DT in Patients With Colorectal Adenocarcinoma. Completed NCT02181465 Phase 2
24 Phase II Trial of Lapatinib & Capecitabine for Patients With Refractory Advanced Colorectal Adenocarcinoma Completed NCT00574171 Phase 2 lapatinib;Capecitabine
25 Efficacy and Safety of Simtuzumab With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma Completed NCT01479465 Phase 2 Simtuzumab;FOLFIRI;Placebo to match simtuzumab
26 DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma Completed NCT00080834 Phase 2 DJ-927
27 Efficacy and Safety of Everolimus in Patients With Metastatic Colorectal Cancer Who Have Failed Prior Targeted Therapy and Chemotherapy Completed NCT00419159 Phase 2 Everolimus (RAD001)
28 Expanded Cohort for Metastatic Colorectal Cancer (MCRC) Using Bevacizumab + Everolimus Completed NCT00597506 Phase 2 Bevacizumab;Everolimus
29 Capecitabine and Thalidomide in Previously Treated Metastatic Colorectal Carcinoma Completed NCT00165217 Phase 2 Capecitabine;Thalidomide
30 Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas Completed NCT01730586 Phase 2 Abraxane
31 Evaluation of Surgically Resected Colorectal Adenomas and Carcinomas After 7 Days Pretreatment With Celecoxib Completed NCT00582660 Phase 2 Celecoxib;Placebo
32 Bryostatin 1 in Treating Patients With Metastatic Colorectal Cancer Completed NCT00003220 Phase 2 bryostatin 1
33 Gefitinib in Treating Patients With Recurrent Metastatic Colorectal Cancer Completed NCT00025350 Phase 2 gefitinib
34 Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone Completed NCT00890305 Phase 2 CT-011;FOLFOX
35 Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver Completed NCT00149396 Phase 1, Phase 2 NV1020
36 1st Line Chemotherapy Alone or With Bevacizumab in Treating Older Patients With Metastatic Colorectal Cancer Completed NCT01417494 Phase 2 Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen);Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab
37 Tarceva, Capecitabine and Oxaliplatin for Metastatic Colorectal Cancer Completed NCT00123851 Phase 2 Tarceva (OSI-774);Capecitabine;Oxaliplatin
38 Erbitux Study of CPT11, Oxaliplatin, UFToral Targeted Therapy Completed NCT01225744 Phase 2 Cetuximab;Irinotecan;Oxaliplatin;UFT
39 Effect of TroVax in Patients Having Colorectal Cancer With Liver Metastases Removed Completed NCT00259844 Phase 2
40 Azacitidine and CAPOX in Metastatic Colorectal Cancer Completed NCT01193517 Phase 1, Phase 2 Azacitidine;Capecitabine;Oxaliplatin;Azacitidine MTD
41 Quinacrine-Capecitabine Combinatorial Therapy for Advanced Stage Colorectal ADenocarcinoma Recruiting NCT01844076 Phase 1, Phase 2 Phase I (Quinacrine);Capecitabine
42 Evaluation of Ocoxin®-Viusid® in Metastatic Colorectal Adenocarcinoma Recruiting NCT03559543 Phase 2
43 FOLFOX + Panitumumab According to a "Stop and go" Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation Recruiting NCT03584711 Phase 2
44 Chemotherapy and/or Metastasectomy in Treating Participants With Metastatic Colorectal Adenocarcinoma With Lung Metastases Recruiting NCT03599752 Phase 2 Chemotherapy
45 Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases Recruiting NCT02185443 Phase 2
46 Study of Nivolumab and Relatlimab in Patients With Microsatellite Stable (MSS) Advanced Colorectal Cancer Recruiting NCT03642067 Phase 2 Nivolumab;Relatlimab
47 Study of Chemotherapy With or Without Hepatic Arterial Infusion for Patients With Unresectable Metastatic Colorectal Cancer to the Liver Recruiting NCT03069950 Phase 2 Floxuridine (FUDR);Irinotecan (CPT-11);FLUOROURACIL;PANITUMUMAB;DEXAMETHASONE;Leucovorin
48 Trial of Liver Resection Versus No Surgery in Patients With Liver and Unresectable Pulmonary Metastases From Colorectal Cancer (Liver Resection With Unresectable Lung Nodules From Colorectal Adenocarcinoma - LUNA) Recruiting NCT02738606 Phase 2 Chemotherapy
49 PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC Recruiting NCT03442569 Phase 2 Panitumumab;Nivolumab;Ipilimumab
50 Open-Label Phase 2 Efficacy Trial of Cancer Macrobeads in Patients With Treatment-Resistant Pancreatic or Colorectal Cancer Recruiting NCT01053013 Phase 2

Search NIH Clinical Center for Colorectal Adenocarcinoma

Genetic Tests for Colorectal Adenocarcinoma

Anatomical Context for Colorectal Adenocarcinoma

MalaCards organs/tissues related to Colorectal Adenocarcinoma:

41
Liver, Colon, Lymph Node, Lung, Testes, Endothelial, Thyroid

Publications for Colorectal Adenocarcinoma

Articles related to Colorectal Adenocarcinoma:

(show top 50) (show all 951)
# Title Authors Year
1
Histology of colorectal adenocarcinoma with double somatic mismatch repair mutations is indistinguishable from those caused by lynch syndrome. ( 29723603 )
2018
2
SCF/c-KIT Signaling Increased Mucin2 Production by Maintaining Atoh1 Expression in Mucinous Colorectal Adenocarcinoma. ( 29786668 )
2018
3
MAPK inhibitors induce serine peptidase inhibitor Kazal type 1 (SPINK1) secretion in BRAF V600E-mutant colorectal adenocarcinoma. ( 29193645 )
2018
4
Collision tumor consisting of a colorectal adenocarcinoma and dissemination of a gastric adenocarcinoma. ( 29326826 )
2018
5
Expression of Epidermal Growth Factor Receptor in Colorectal Adenocarcinoma and its Correlation with Clinicopathological Factors. ( 29950257 )
2018
6
In vivo identification of novel TGIF2LX target genes in colorectal adenocarcinoma using the cDNA-AFLP method. ( 29960902 )
2018
7
Cellular mechanism of resistance of human colorectal adenocarcinoma cells against apoptosis-induction by Russell's Viper venom l-amino acid oxidase (Rusvinoxidase). ( 29702182 )
2018
8
Hepatobiliary and Pancreatic: Hepatic nodules in a patient with familial adenomatous polyposis and colorectal adenocarcinoma. ( 29284077 )
2018
9
Localized lymphoid hyperplasia of the spleen mimicking metastatic colorectal adenocarcinoma. ( 29952067 )
2018
10
MET amplification, expression, and exon 14 mutations in colorectal adenocarcinoma. ( 29641976 )
2018
11
Predictors for local recurrence and distant metastasis of mucinous colorectal adenocarcinoma. ( 29361368 )
2018
12
Nuclear expression of claudin-3 in human colorectal adenocarcinoma cell lines and tissues. ( 29285188 )
2018
13
Lysine-specific demethylase 2A expression is associated with cell growth and cyclin D1 expression in colorectal adenocarcinoma. ( 29683067 )
2018
14
Expression of GAEC1 mRNA and protein and its association with clinical and pathological parameters of patients with colorectal adenocarcinoma. ( 29337242 )
2018
15
Validation of a targeted next-generation sequencing approach to detect mismatch repair deficiency in colorectal adenocarcinoma. ( 29955144 )
2018
16
Investigating the association between African spontaneously fermented dairy products, faecal carriage of Streptococcus infantarius subsp. infantarius and colorectal adenocarcinoma in Kenya. ( 29079186 )
2018
17
Triple primary malignancies in a patient with colorectal adenocarcinoma: A case report. ( 29216528 )
2018
18
Decreased Expression of the Polarity Regulatory PAR Complex Predicts Poor Prognosis of the Patients with Colorectal Adenocarcinoma. ( 29220829 )
2018
19
High microRNA-28-5p expression in colorectal adenocarcinoma predicts short-term relapse of node-negative patients and poor overall survival of patients with non-metastatic disease. ( 29688883 )
2018
20
Colorectal Adenocarcinoma with an Alternative Serrated Pathway. ( 29805354 )
2018
21
Expression and location of IL-17A, E, F and their receptors in colorectal adenocarcinoma: Comparison with benign intestinal disease. ( 29548809 )
2018
22
The Smad4/PTEN Expression Pattern Predicts Clinical Outcomes in Colorectal Adenocarcinoma. ( 29056035 )
2018
23
CT-based Radiomics Signature to Discriminate High-grade From Low-grade Colorectal Adenocarcinoma. ( 29503175 )
2018
24
Long Noncoding RNAs in Colorectal Adenocarcinoma; an in silico Analysis. ( 29948619 )
2018
25
Anatomical subsite can modify the association between meat and meat compounds and risk of colorectal adenocarcinoma: findings from three large US cohorts. ( 29873077 )
2018
26
p38 inhibitor inhibits the apoptosis of cowanin-treated human colorectal adenocarcinoma cells. ( 29620273 )
2018
27
Metformin and aspirin treatment could lead to an improved survival rate for Type 2 diabetic patients with stage II and III colorectal adenocarcinoma relative to non-diabetic patients. ( 29456855 )
2018
28
Ultrastructure of colorectal adenocarcinoma and peritumoral tissue in untreated patients. ( 29419351 )
2018
29
PIWI-interacting RNA-54265 is oncogenic and a potential therapeutic target in colorectal adenocarcinoma. ( 30555542 )
2018
30
Down regulation of lncRNA MEG3 promotes colorectal adenocarcinoma cell proliferation and inhibits the apoptosis by up-regulating TGF-β1 and its downstream sphingosine kinase 1. ( 30556866 )
2018
31
Differences in overall survival and mutation prevalence between right- and left-sided colorectal adenocarcinoma. ( 30505575 )
2018
32
Investigation of the Anticancer Mechanism of Isoorientin Isolated from Eremurus Spectabilis Leaves via Cell Cycle Pathways in HT-29 Human Colorectal Adenocarcinoma Cells. ( 30515037 )
2018
33
The prognostic role of tumor associated glycoprotein 72 (TAG-72) in stage II and III colorectal adenocarcinoma. ( 30466765 )
2018
34
Isolated bone marrow metastases of colorectal adenocarcinoma. ( 30414232 )
2018
35
Evaluation of Peritumoral Fibrosis in Metastatic Colorectal Adenocarcinoma to the Liver Using Digital Image Analysis. ( 30339201 )
2018
36
Worst outcomes according to RAS mutation variants: an analysis in patients with metastatic colorectal adenocarcinoma. ( 30358195 )
2018
37
Identification of LINC01234 and MIR210HG as novel prognostic signature for colorectal adenocarcinoma. ( 30362555 )
2018
38
GLI1 promotes cancer stemness through intracellular signaling pathway PI3K/Akt/NFκB in colorectal adenocarcinoma. ( 30321514 )
2018
39
Multidisciplinary team intervention associated with improved survival for patients with colorectal adenocarcinoma with liver or lung metastasis. ( 30323980 )
2018
40
The Effect of LncRNA H19/miR-194-5p Axis on the Epithelial-Mesenchymal Transition of Colorectal Adenocarcinoma. ( 30278464 )
2018
41
Computational analysis of mRNA expression profiles identifies a novel triple-biomarker model as prognostic predictor of stage II and III colorectal adenocarcinoma patients. ( 30214289 )
2018
42
ARHGEF7 promotes metastasis of colorectal adenocarcinoma by regulating the motility of cancer cells. ( 30132516 )
2018
43
Early detection of colorectal adenocarcinoma: a clinical decision support tool based on plasma porphyrin accumulation and risk factors. ( 30134852 )
2018
44
Expression of leptin in colorectal adenocarcinoma showed significant different survival patterns associated with tumor size, lymphovascular invasion, distant metastasis, local recurrence, and relapse of disease in the western province of Saudi Arabia. ( 30142858 )
2018
45
Loss of BAP1 Expression Occurs Rarely to Never in Colorectal Adenocarcinoma. ( 28362705 )
2018
46
Additional lymphadenectomy might not improve survival of patients with resectable metastatic colorectal adenocarcinoma of T4 stage, proximal location, poor/undifferentiation, or N3/N4 stages: a large population-based study. ( 30026839 )
2018
47
SCF/c-KIT signaling promotes mucus secretion of colonic goblet cells and development of mucinous colorectal adenocarcinoma. ( 30034943 )
2018
48
Nuclear Expression of CD133 Is Associated with Good Prognosis in Patients with Colorectal Adenocarcinoma. ( 30061254 )
2018
49
[Polymorphisms of mTORC1 genes and risk of primary colorectal adenocarcinoma in Chinese populations]. ( 29996312 )
2018
50
Intermittent low dose irradiation enhances the effectiveness of radio- and chemo-therapy for human colorectal adenocarcinoma cell line HT-29. ( 28560404 )
2017

Variations for Colorectal Adenocarcinoma

Expression for Colorectal Adenocarcinoma

Search GEO for disease gene expression data for Colorectal Adenocarcinoma.

Pathways for Colorectal Adenocarcinoma

Pathways related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 66)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.52 BRAF CDK8 CTNNB1 EGFR HRAS KRAS
2
Show member pathways
12.98 BRAF CDH1 CDX2 CTNNB1 HRAS KRAS
3 12.78 BRAF EGFR HRAS KRAS TP53
4
Show member pathways
12.77 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
5
Show member pathways
12.75 BRAF CDH1 EGFR HRAS KRAS TP53
6
Show member pathways
12.7 BRAF EGFR HRAS KRAS TP53
7
Show member pathways
12.7 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
8 12.68 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
9
Show member pathways
12.67 BRAF CDH1 CTNNB1 HRAS KRAS TP53
10
Show member pathways
12.55 CTNNB1 EGFR HRAS KRAS MSH2 TP53
11 12.54 AURKA CDK8 MLH1 MSH2 TP53
12
Show member pathways
12.52 BRAF EGFR HRAS KRAS TP53
13
Show member pathways
12.52 BRAF CDH1 CDX2 CTNNB1 EGFR HRAS
14
Show member pathways
12.5 BRAF EGFR HRAS KRAS TP53
15
Show member pathways
12.46 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
16
Show member pathways
12.45 CTNNB1 EGFR HRAS KRAS TP53
17 12.43 CTNNB1 HRAS KRAS TP53
18
Show member pathways
12.43 CTNNB1 EGFR HRAS KRAS
19
Show member pathways
12.43 BRAF CTNNB1 EGFR HRAS KRAS
20
Show member pathways
12.41 BRAF CTNNB1 HRAS KRAS
21
Show member pathways
12.38 BRAF CDH1 CTNNB1 EGFR HRAS KRAS
22
Show member pathways
12.29 BRAF FGFBP1 HRAS KRAS
23
Show member pathways
12.27 BRAF HRAS KRAS TP53
24 12.24 BRAF CTNNB1 EGFR HRAS KRAS TP53
25
Show member pathways
12.22 BRAF EGFR HRAS KRAS TP53
26
Show member pathways
12.2 BRAF HRAS KRAS TP53
27
Show member pathways
12.17 BRAF HRAS KRAS TP53
28 12.15 EGFR HRAS KRAS TP53
29 12.14 AURKA BRAF EGFR HRAS KRAS
30
Show member pathways
12.12 BRAF EGFR HRAS KRAS
31 12.09 EGFR MLH1 MSH2 TP53
32
Show member pathways
12.08 EGFR HRAS KRAS TP53
33 12.05 CDH1 CTNNB1 HRAS KRAS
34 12.03 BRAF EGFR HRAS KRAS TP53
35 12.01 CTNNB1 HRAS KRAS TP53
36 12 CTNNB1 HRAS KRAS TP53
37 11.93 BRAF CTNNB1 EGFR HRAS KRAS TP53
38
Show member pathways
11.88 EGFR HRAS KRAS
39
Show member pathways
11.88 CDH1 CTNNB1 EGFR
40 11.85 EGFR HRAS KRAS
41
Show member pathways
11.82 BRAF HRAS KRAS
42 11.78 BRAF CDH1 CTNNB1 EGFR KRAS MLH1
43 11.76 MLH1 MSH2 TP53
44 11.75 CDH1 CTNNB1 EGFR
45 11.71 BRAF CDH1 EGFR HRAS KRAS TP53
46 11.7 HRAS KRAS TP53
47
Show member pathways
11.7 BRAF HRAS KRAS
48 11.66 EGFR HRAS KRAS TP53
49 11.65 BRAF HRAS KRAS
50 11.63 EGFR HRAS KRAS

GO Terms for Colorectal Adenocarcinoma

Cellular components related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 flotillin complex GO:0016600 8.62 CDH1 CTNNB1

Biological processes related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.92 BRAF CTNNB1 HRAS KRAS TP53
2 MAPK cascade GO:0000165 9.89 BRAF EGFR HRAS KRAS
3 cell proliferation GO:0008283 9.88 CTNNB1 EGFR HRAS PIM2 TP53
4 positive regulation of transcription, DNA-templated GO:0045893 9.88 CDH1 CDX2 CTNNB1 EGFR PIM2 TP53
5 Ras protein signal transduction GO:0007265 9.75 HRAS KRAS TP53
6 cellular response to drug GO:0035690 9.74 BRAF EGFR TP53
7 positive regulation of cell proliferation GO:0008284 9.73 CDX2 CTNNB1 EGFR FGFBP1 HRAS KRAS
8 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.71 HRAS KRAS MUC2
9 positive regulation of MAP kinase activity GO:0043406 9.69 EGFR HRAS KRAS
10 negative regulation of neuron apoptotic process GO:0043524 9.62 BRAF HRAS KRAS MSH2
11 positive regulation of isotype switching to IgG isotypes GO:0048304 9.6 MLH1 MSH2
12 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.58 EGFR TP53
13 entry of bacterium into host cell GO:0035635 9.56 CDH1 CTNNB1
14 positive regulation of fibroblast growth factor receptor signaling pathway GO:0045743 9.55 CTNNB1 FGFBP1
15 response to isolation stress GO:0035900 9.49 HRAS KRAS
16 cellular response to indole-3-methanol GO:0071681 9.46 CDH1 CTNNB1
17 positive regulation of isotype switching to IgA isotypes GO:0048298 9.43 MLH1 MSH2
18 negative regulation of cell proliferation GO:0008285 9.43 CTNNB1 FABP6 FGFBP1 HRAS PIM2 TP53
19 somatic recombination of immunoglobulin gene segments GO:0016447 9.37 MLH1 MSH2
20 negative regulation of apoptotic process GO:0043066 9.17 AURKA BRAF CEACAM5 CTNNB1 EGFR PIM2
21 somatic recombination of immunoglobulin genes involved in immune response GO:0002204 9.16 MLH1 MSH2

Molecular functions related to Colorectal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.88 AURKA BRAF CDK8 EGFR PIM2
2 protein heterodimerization activity GO:0046982 9.85 AURKA BRAF CTNNB1 EGFR TP53
3 protein kinase binding GO:0019901 9.77 AURKA CTNNB1 EGFR MSH2 TP53
4 ATP binding GO:0005524 9.76 AURKA BRAF CDK8 EGFR MLH1 MSH2
5 chromatin binding GO:0003682 9.72 CTNNB1 EGFR MLH1 MSH2 TP53
6 protein phosphatase binding GO:0019903 9.58 CTNNB1 EGFR TP53
7 mismatched DNA binding GO:0030983 9.43 MLH1 MSH2
8 enzyme binding GO:0019899 9.35 CTNNB1 EGFR MLH1 MSH2 TP53
9 guanine/thymine mispair binding GO:0032137 9.26 MLH1 MSH2
10 nucleotide binding GO:0000166 9.1 AURKA BRAF EGFR HRAS KRAS PIM2

Sources for Colorectal Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....